1. Home
  2. PAI vs TTRX Comparison

PAI vs TTRX Comparison

Compare PAI & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Investment Grade Income Fund Inc.

PAI

Western Asset Investment Grade Income Fund Inc.

HOLD

Current Price

$12.25

Market Cap

116.2M

Sector

Finance

ML Signal

HOLD

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$3.72

Market Cap

107.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PAI
TTRX
Founded
1973
2015
Country
United States
United States
Employees
N/A
2
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.2M
107.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PAI
TTRX
Price
$12.25
$3.72
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
18.5K
22.2K
Earning Date
01-01-0001
05-31-2026
Dividend Yield
4.78%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.72
$2.57
52 Week High
$13.22
$5.98

Technical Indicators

Market Signals
Indicator
PAI
TTRX
Relative Strength Index (RSI) 48.58 61.70
Support Level $12.08 $3.55
Resistance Level $12.35 $3.92
Average True Range (ATR) 0.10 0.19
MACD 0.00 0.04
Stochastic Oscillator 40.74 85.42

Price Performance

Historical Comparison
PAI
TTRX

About PAI Western Asset Investment Grade Income Fund Inc.

Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. Its primary investment objective is to seek a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. To a lesser extent, the fund also invests in privately placed debt securities and in certain equity securities. Capital appreciation is its secondary investment objective. The fund invests a majority of its net assets in fixed income securities that are rated in the Baa or BBB categories or above at the time of purchase by one or more Nationally Recognized Statistical Rating Organizations (NRSROs) or unrated securities of comparable quality at the time of purchase (as determined by the investment adviser).

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: